Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Trimetazidine on Radiotherapy-induced Heart Damage in Lung Tumor Patients Treated With Stereotactic Body Radiotherapy.

NCT04939857 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT04939857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04939857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Trimetazidine on Radiotherapy-induced Heart Damage in Lung Tumor Patients Treated With Stereotactic Body Radiotherapy.
Lead sponsor
Peking University Third Hospital
Phase
Phase 2/3
Overall status
Unknown status
Start date
June 25, 2021
Completion date
August 31, 2022
Enrollment
80 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cardiotoxicity